Genmab A/S (NASDAQ:GMAB) to Post FY2024 Earnings of $0.88 Per Share, William Blair Forecasts

Genmab A/S (NASDAQ:GMAB) – Equities research analysts at William Blair dropped their FY2024 earnings per share estimates for shares of Genmab A/S in a research note issued on Wednesday, April 17th. William Blair analyst M. Phipps now anticipates that the company will earn $0.88 per share for the year, down from their previous forecast of $0.89. The consensus estimate for Genmab A/S’s current full-year earnings is $1.06 per share. William Blair also issued estimates for Genmab A/S’s FY2025 earnings at $1.05 EPS.

Several other brokerages also recently commented on GMAB. Citigroup downgraded Genmab A/S from a “neutral” rating to a “sell” rating in a research note on Monday, January 22nd. HC Wainwright restated a “buy” rating and issued a $50.00 price target on shares of Genmab A/S in a research note on Thursday, April 4th. Truist Financial reaffirmed a “buy” rating and issued a $50.00 target price on shares of Genmab A/S in a report on Tuesday, March 26th. BMO Capital Markets raised Genmab A/S from a “market perform” rating to an “outperform” rating and raised their target price for the stock from $46.00 to $48.00 in a report on Friday, February 23rd. Finally, Morgan Stanley reaffirmed an “underweight” rating on shares of Genmab A/S in a report on Tuesday, March 26th. Three investment analysts have rated the stock with a sell rating, two have issued a hold rating and eight have issued a buy rating to the stock. Based on data from MarketBeat.com, the company currently has a consensus rating of “Hold” and an average price target of $48.50.

Genmab A/S Trading Down 0.7 %

Shares of GMAB opened at $28.33 on Friday. The business’s fifty day simple moving average is $29.36 and its two-hundred day simple moving average is $30.34. Genmab A/S has a 12 month low of $26.32 and a 12 month high of $42.72. The company has a market cap of $18.73 billion, a price-to-earnings ratio of 29.51, a P/E/G ratio of 2.05 and a beta of 0.99.

Genmab A/S (NASDAQ:GMAB) last posted its quarterly earnings results on Wednesday, February 14th. The company reported $0.36 earnings per share for the quarter, topping the consensus estimate of $0.34 by $0.02. The company had revenue of $675.29 million for the quarter, compared to the consensus estimate of $678.14 million. Genmab A/S had a return on equity of 18.06% and a net margin of 26.50%.

Institutional Investors Weigh In On Genmab A/S

Institutional investors and hedge funds have recently bought and sold shares of the business. NewEdge Wealth LLC raised its holdings in Genmab A/S by 50.7% during the fourth quarter. NewEdge Wealth LLC now owns 119,989 shares of the company’s stock valued at $3,820,000 after acquiring an additional 40,382 shares during the period. Keybank National Association OH bought a new stake in shares of Genmab A/S in the third quarter worth about $1,154,000. Knights of Columbus Asset Advisors LLC increased its holdings in shares of Genmab A/S by 16.8% in the third quarter. Knights of Columbus Asset Advisors LLC now owns 5,712 shares of the company’s stock worth $201,000 after purchasing an additional 822 shares during the last quarter. China Universal Asset Management Co. Ltd. increased its holdings in shares of Genmab A/S by 350.7% in the fourth quarter. China Universal Asset Management Co. Ltd. now owns 4,845 shares of the company’s stock worth $154,000 after purchasing an additional 3,770 shares during the last quarter. Finally, Northern Trust Corp increased its holdings in shares of Genmab A/S by 83.3% in the third quarter. Northern Trust Corp now owns 559,044 shares of the company’s stock worth $19,717,000 after purchasing an additional 254,042 shares during the last quarter. 7.07% of the stock is owned by institutional investors.

About Genmab A/S

Genmab A/S develops antibody therapeutics for the treatment of cancer and other diseases primarily in Denmark. The company markets DARZALEX, a human monoclonal antibody for the treatment of patients with multiple myeloma (MM); teprotumumab for the treatment of thyroid eye disease; and Amivantamab for advanced or metastatic gastric or esophageal cancer and NSCLC.